Atlas Private Wealth Advisors purchased a new stake in Biogen Inc. (NASDAQ:BIIB) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 301 shares of the biotechnology company’s stock, valued at approximately $84,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Hudock Inc. lifted its stake in shares of Biogen by 40.0% during the fourth quarter. Hudock Inc. now owns 140 shares of the biotechnology company’s stock valued at $34,000 after buying an additional 40 shares during the period. NBT Bank N A NY lifted its stake in shares of Biogen by 4.5% during the first quarter. NBT Bank N A NY now owns 930 shares of the biotechnology company’s stock valued at $260,000 after buying an additional 40 shares during the period. Cetera Advisor Networks LLC raised its stake in Biogen by 2.5% during the fourth quarter. Cetera Advisor Networks LLC now owns 1,718 shares of the biotechnology company’s stock worth $421,000 after purchasing an additional 42 shares during the period. Clean Yield Group raised its stake in Biogen by 0.3% during the first quarter. Clean Yield Group now owns 13,254 shares of the biotechnology company’s stock worth $3,708,000 after purchasing an additional 42 shares during the period. Finally, Shorepoint Capital Partners LLC raised its stake in Biogen by 2.0% during the fourth quarter. Shorepoint Capital Partners LLC now owns 2,184 shares of the biotechnology company’s stock worth $535,000 after purchasing an additional 43 shares during the period. 83.51% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ BIIB opened at $275.31 on Tuesday. The stock’s 50-day moving average price is $269.29 and its two-hundred day moving average price is $263.93. The company has a market cap of $41.45 billion, a PE ratio of 9.11, a PEG ratio of 1.04 and a beta of 0.53. The company has a current ratio of 2.06, a quick ratio of 1.79 and a debt-to-equity ratio of 0.69. Biogen Inc. has a 1 year low of $223.25 and a 1 year high of $363.92.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Wednesday, April 21st. The biotechnology company reported $5.34 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $5.06 by $0.28. Biogen had a net margin of 35.63% and a return on equity of 51.00%. The business had revenue of $2.69 billion for the quarter, compared to analyst estimates of $2.67 billion. During the same quarter in the previous year, the business earned $9.14 earnings per share. The firm’s revenue was down 23.8% compared to the same quarter last year. Research analysts forecast that Biogen Inc. will post 33.63 EPS for the current fiscal year.

A number of equities analysts have weighed in on the stock. SVB Leerink cut their price target on shares of Biogen from $430.00 to $380.00 and set an “outperform” rating on the stock in a research note on Thursday, February 4th. DZ Bank downgraded shares of Biogen from a “buy” rating to a “hold” rating and set a $264.00 target price on the stock. in a research note on Friday, February 5th. Cantor Fitzgerald lowered their price target on shares of Biogen from $278.00 to $268.00 and set a “neutral” rating for the company in a report on Wednesday, February 17th. Stifel Nicolaus raised shares of Biogen from a “hold” rating to a “buy” rating and lifted their price target for the company from $258.00 to $358.00 in a report on Friday, January 29th. Finally, Piper Sandler decreased their price target on shares of Biogen from $265.00 to $250.00 and set a “neutral” rating for the company in a report on Wednesday, February 3rd. Four equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have assigned a buy rating to the company. Biogen has an average rating of “Hold” and an average target price of $305.57.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis.

Further Reading: How to calculate compound interest

Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB).

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.